<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00160056</url>
  </required_header>
  <id_info>
    <org_study_id>HB2-001</org_study_id>
    <nct_id>NCT00160056</nct_id>
  </id_info>
  <brief_title>The Effect of Antecedent Hypoglycaemia on β2-adrenergic Sensitivity</brief_title>
  <official_title>The Effect of Antecedent Hypoglycaemia on β2-adrenergic Sensitivity in Subjects With Homozygous Arg16 and gly16 Polymorphism of the β2-adrenergic Receptor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      Hypoglycaemia unawareness is a common complication in patients with type 1 diabetes and with
      insulin-treated type 2 diabetes of long duration. The loss of autonomic symptoms to
      hypoglycemia does not solely depend on loss of adrenaline responses.Differences in
      sensitivity to catecholamines may also be involved.

      Reconciling the data on β2-adrenergic receptor polymorphism to those on loss of β-adrenergic
      sensitivity in diabetic patients with hypoglycemia unawareness, we hypothesize that
      hypoglycemia unawareness is at least partly the result of desensitization of the
      β2-adrenergic receptor and that patients who are homozygous for arginine at codon 16 are
      particularly susceptible for this desensitization process, whereas patients who are
      homozygous for glycine at codon 16 are resistant for desensitization.

      Objectives

        1. To determine whether, and if so to what extent, antecedent hypoglycemia reduces
           β2-adrenergic sensitivity in healthy subjects with Arg16 homozygosity.

        2. To investigate whether or not healthy subjects with Gly16 homozygosity are resistant to
           desensitization

        3. To confirm that antecedent hypoglycemia reduces the heart rate response to isoproterenol
           and to assess to what extent this reduced response is mediated by impairments in
           baroreflex sensitivity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes</condition>
  <condition>Hypoglycemia Unawareness</condition>
  <arm_group>
    <arm_group_label>Hypoglycemia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intrerfvention is a hypoglycemic stimulus</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hypoglycemia</intervention_name>
    <arm_group_label>Hypoglycemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Homozygous for Arginine at codon 16 or homozygous Gly at codon 16

          -  No regular usage of medication other than oral contraceptives

        Exclusion Criteria:

          -  History of cerebrovascular, cardiovascular, or peripheral vascular disease

          -  Smoking

          -  Alcohol usage of more than 10 units per week

          -  Inability to abstain from xanthine-derivatives (coffee, tea, cola, chocolate, cacao)
             or alcohol for 2 days

          -  BMI above 30 kg/m2

          -  Participation to any other trial in the preceding 3 months

          -  Ongoing disease of any kind

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Smits, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>May 8, 2015</last_update_submitted>
  <last_update_submitted_qc>May 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoglycemia unawareness</keyword>
  <keyword>Diabetes</keyword>
  <keyword>adrenal receptor</keyword>
  <keyword>adrenerg respons</keyword>
  <keyword>adrenergic beta-agonists</keyword>
  <keyword>salbutamol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Unconsciousness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

